-
Published22/02/2024
-
Deadline31/01/2026
-
Opening of tenders02/02/2026
-
Today18/09/2026
Utilities
- indicates text translated automatically in your browsing language
Conclusion of non-exclusive discount agreements pursuant to Paragraph 130a(8)/130c(1) of the SGB V on medicinal products containing the active substance mesalazine (A07EC02) as part of an open-house model.
Conclusion of non-exclusive discount agreements pursuant to Section 130a(8)/130c(1) of the SGB V on medicinal products containing the active ingredient mesalazine (A07EC02) within the period from 1 April 2024 to 31 March 2026, with the possibility of concluding contracts at any time (open-house model). In the open house procedure, medicinal products are excluded in accordance with the BfArM list under § 35(5a) SGB V (Paediatric Medicines).
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.